In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround ...

Cellares' forward momentum continues, as the company announced April 1, 2025, a notable milestone for its Cell Shuttle.

Up to $3 billion in pharmaceuticals currently used in the United States (U.S.) depend on Canadian manufacturing, according to ...

| Project Optimus is changing the landscape of oncology drug development by redefining dose optimization standards. Learn how ...

We didn’t start Model to launch a company—we started it because no one else met our standards,” says Dr. Daniel Haders II, CEO and founder of Model Medicines. On this episode of Vanguards of Health ...

Though Isomorphic is burning through millions in R&D costs now, investors have high hopes for the potential of AI drug ...

Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

Strengthened leadership team with key appointments, including Barry Quart, Pharm.D. as CEO, and David Szekeres as President, bringing deep ...

Artificial intelligence (AI) is making significant strides in various fields, with drug discovery being one of the most impactful areas. The process of developing new drugs has traditionally been a ...

Researchers at the University of Missouri have developed an innovative electrochemistry method to create new molecules using ...

As of January 31st, 2025, we held $12.9 million in cash compared to $3.5 million at the fiscal year-end 2024. This increase was driven by the successful execution of our ATM program, through which we ...